Oramed Pharmaceuticals (ORMP) EBT (2011 - 2026)

Oramed Pharmaceuticals has reported EBT for 15 years, with the latest figure at $49.4 million in Q1 2026.

• For the quarter ending Q1 2026, EBT rose 800.48% year-over-year to $49.4 million; the trailing twelve-month figure through Mar 2026 stood at $131.8 million (up 637.79% YoY), and the FY2025 full-year result was $75.3 million, up 573.14% from the prior year.
• EBT for Q1 2026 stood at $49.4 million, up from $9.8 million in the prior quarter.
• The five-year high for EBT was $59.5 million in Q3 2025, with the low at -$18.5 million in Q3 2024.
• Historically, EBT has averaged $4.1 million across 5 years, with a median of -$3.3 million in 2023.
• Annual changes were most pronounced in 2024 — EBT jumped 925.44% — and 2025, when it tumbled 560.1%.
• Oramed Pharmaceuticals' EBT stood at -$12.3 million in 2022, then surged by 208.49% to $13.3 million in 2023, then sank by 173.58% to -$9.8 million in 2024, then surged by 200.14% to $9.8 million in 2025, then surged by 404.64% to $49.4 million in 2026.
• The last three EBT figures came in at $49.4 million (Q1 2026), $9.8 million (Q4 2025), and $59.5 million (Q3 2025), per Business Quant data.